Conversely effective

Cumulative flu incidence among Cleveland Clinic Ohio employees. Red line — unvaccinated, blue line — vaccinated.

https://www.medrxiv.org/content/10.1101/025.01.30.25321421v4.full.pdf+html

Abstract

Introduction. The intent of this survey was to measure the efficacy of the influenza vaccine during the 2024-2025 epidemic season.

Methods. The survey included Cleveland Clinic employees employed in Ohio on 1 October 2024. The cumulative incidence of influenza among vaccine and non-vaccinated subjects was compared over the next 33 weeks. The protection provided by the vaccination (assessed as a time-dependent variable) was assessed by a multi-factorial regression of Cox's proportional risk, taking into account influenza activity as an effect modifier.

Results. Of the 53,402 employees, 43,920 (82.2%) were vaccinated by the end of the study. Flu occurred in 1130 (2.12%) subjects during the study. Cumulative influenza incidence was akin in vaccinated and unvaccinated conditions at first, but with time the cumulative influenza incidence grew faster among the vaccinated than the unvaccinated. In a multi-factoral regression analysis of Cox's proportional risk, the hazard of influenza was not importantly different in low periods (HR, 0.70; 95% CI, 0.42–1.15); P = 0.15) or mean (HR, 1.20; 95% CI, 0.86–36 1.67; P = 0.28) influenza activity but was importantly higher in the vaccinated state than in the unvaccinated state erstwhile the flu activity was high (HR, 1.33; 95% CI, 1.07–1.64; P = 0.009).

Conclusions. In this survey the protective effect of influenza vaccination has not been demonstrated among adults of working age during the respiratory epidemic period 2024–2025. However, it was found that influenza vaccination was associated with a higher hazard of influenza during advanced flu activity.

The work has not yet been published in the magazine, and this may inactive take time, knowing the tendency of mainstream medical journals to print works questioning the authoritative narrative. However, this is simply a major survey by a serious medical centre known for its reliability, so we can take it seriously.

I think there's adequate data of this kind to see why the next appeals of medical authorities are serving. This is not about our health, it is about the gross of the medical industry. Even if they tell us that we can be vaccinated for free, we pay for it anyway through our wellness contribution or taxes. We become poorer and sicker, and they make money.

Several years ago, even Anthony Fauci, the criminal manager of NIAID NIH, liable in the United States for a catastrophic consequence to Covid-1984, admitted this. In the introduction to the 2022 publication entitled Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and another respiration viruses (A fresh look at next generation vaccines against coronaviruses, influenza viruses and another respiratory viruses) admits:

Replication viruses in the human respiratory mucosa without systemic infection, including influenza virus kind A, SARS-CoV-2, endemic coronaviruses, RSV and many another “cold” viruses, origin crucial mortality and morbidity and pose a serious threat to public health. Since these viruses do not usually origin complete and permanent protective immunity themselves, so far, they have not been effectively controlled with licensed or experimental vaccines. In this review, we examine the challenges that make it hard to make effective vaccines for the mucosa of the airways, stressing that all these viruses replicate highly rapidly in the surface epithelium and are rapidly transferred to another hosts in a short time before adaptive immune responses are full mobilised.

[...]

https://doi.org/10.1016/j.chom.2022.11.016

He does not mention any harmful side effects and complications in his work, which, unlike protective action, are certain. Of course, inefficiency and possible complications do not hinder the sale of these wonderful vaccines to all of us. This is simply a science, and you shut up and go back to the dark garden.